Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Leukotriene Receptor Antibodies

The leukotriene receptors are activated by the endogenous ligands leukotrienes (LT), synthesized from lipoxygenase metabolism of arachidonic acid. The human BLT1 receptor is the high affinity LTB4 receptor whereas the BLT2 receptor in addition to being a low-affinity LTB4 receptor also binds several other lipoxygenase-products, such as 12S-HETE, 12S-HPETE, 15S-HETE, and the thromboxane synthase product 12-hydroxyheptadecatrienoic acid. The BLT receptors mediate chemotaxis and immunomodulation in several leukocyte populations and are in addition expressed on non-myeloid cells, such as vascular smooth muscle and endothelial cells. The receptors for the cysteinyl-leukotrienes (i.e. LTC4, LTD4 and LTE4) are termed CysLT1 and CysLT2 and exhibit distinct expression patterns in human tissues, mediating for example smooth muscle cell contraction, regulation of vascular permeability, and leukocyte activation. There is also evidence in the literature for additional CysLT receptor subtypes, derived from functional in vitro studies, radioligand binding and in mice lacking both CysLT1 and CysLT2 receptors.

Close filters
No results were found for the filter!
NEW
pT329/pT330-BLT2 (phospho-Leukotriene Receptor BLT2 Antibody)
pT329/pT330-BLT2 (phospho-Leukotriene Receptor...
Threonine329/Threonine330 (T329/T330) is a major phosphorylation site of the BLT2 receptor. The pT329/pT330-BLT2 antibody detects phosphorylation in response to high- and low-efficacy agonists and after PKC activation. T329/T330...
$ 375.00 *
NEW
Agonist-induced Serine320/Threonine324 phosphorylation of the Leukotriene Receptor BLT2.
pS320/pT324-BLT2 (phospho-Leukotriene Receptor...
Serine320/Threonine324 (S320/T324) is a major phosphorylation site of the BLT2 receptor. The pS320/pT324-BLT2 antibody detects phosphorylation in response to high- and low-efficacy agonists and after PKC activation. S320/T324...
$ 375.00 *

For more information on hydroxycarboxylic acid receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Bäck M, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev. 2011 Sep;63(3):539-84. doi: 10.1124/pr.110.004184. PMID: 21771892.

Bäck M, Powell WS, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE. Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br J Pharmacol. 2014 Aug;171(15):3551-74. doi: 10.1111/bph.12665. Epub 2014 Jul 12. PMID: 24588652; PMCID: PMC4128057.

For more information on hydroxycarboxylic acid receptor pharmacology please refer to the IUPHAR database. For further reading refer to: Bäck M, Dahlén SE, Drazen JM, Evans JF, Serhan CN,... read more »
Close window
Leukotriene Receptor Antibodies

For more information on hydroxycarboxylic acid receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Bäck M, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE. International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev. 2011 Sep;63(3):539-84. doi: 10.1124/pr.110.004184. PMID: 21771892.

Bäck M, Powell WS, Dahlén SE, Drazen JM, Evans JF, Serhan CN, Shimizu T, Yokomizo T, Rovati GE. Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br J Pharmacol. 2014 Aug;171(15):3551-74. doi: 10.1111/bph.12665. Epub 2014 Jul 12. PMID: 24588652; PMCID: PMC4128057.

Recently viewed